Core Viewpoint - The stock of Insilico Medicine (03696) surged over 11% on its second day of trading, reaching HKD 33.62, nearly a 40% increase from its IPO price of HKD 24.05 [1] Company Summary - Insilico Medicine, established in 2014, is a leading company in AI-driven drug discovery and development in China [1] - By December 10, 2025, the company is expected to generate over 20 clinical or IND application-stage assets through its proprietary generative AI platform, Pharma.AI [1] - Three of these assets have been licensed to international pharmaceutical companies, with a total contract value of up to USD 2.1 billion, alongside one Phase II asset currently in self-development [1] Industry Summary - According to Frost & Sullivan, the AI drug discovery and development (AIDD) market is projected to grow from USD 11.9 billion in 2023 to USD 74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6% [1]